The EPS beat and narrowing loss are positive for a micro-cap biotech, but the $9.5M cash runway (approx. 5-6 quarters at current burn) and reliance on ATM financing introduce dilution risk. Watch for Phase 2 ARDS data in H2 2026 and the ATS presentation on May 20 for near-term catalysts. The non-dilutive collaborations reduce capital burden but are small in absolute size.
Price Chart
Executive Summary
MiNK Therapeutics reported Q1 2026 EPS of -$0.57, beating consensus of -$0.77 by 26%, with net loss narrowing to $2.7M from $2.8M YoY. The company initiated a randomized Phase 2 trial for agenT-797 in acute lung injury, secured non-dilutive funding for pipeline expansion, and ended the quarter with $9.5M cash after repaying a $5.2M convertible note. The EPS beat is notable for a clinical-stage biotech, but the cash burn and early-stage pipeline keep the impact moderate.
Key Financial Metrics
Key Facts
- Q1 2026 EPS -$0.57 vs consensus -$0.77 (26% beat)
- Net loss $2.7M vs $2.8M YoY; net loss per share improved from -$0.70 to -$0.57
- Cash and equivalents $9.5M as of March 31, 2026, down from $13.4M at year-end 2025
- Repaid $5.2M Agenus convertible note; raised $3.0M via ATM during Q1
- Initiated randomized Phase 2 trial for agenT-797 in severe acute lung injury/ARDS; preliminary data expected H2 2026
- Non-dilutive collaboration with C-Further provides up to $1.1M for PRAME-targeted iNKT therapy in pediatric cancers
- AACR/ASGCT data showed 77% disease control rate in PD-1 refractory gastroesophageal cancer; median PFS 6.9 months with immune induction vs 3.5 months without
- Upcoming ATS presentation on agenT-797 + N-803 for persistent Coccidioides infection on May 20, 2026
Financial Impact
EPS beat of 26% on a -$0.77 consensus; net loss improved $0.1M YoY; cash burn $1.7M in operations during Q1
Risk Factors
- Cash runway limited to ~5-6 quarters at current burn rate; may require additional financing
- Phase 2 ARDS trial is early-stage with binary outcome risk; no approved pharmacologic therapies exist for ARDS
- ATM program dilutes existing shareholders; $3.0M raised in Q1
- Stock is micro-cap ($52M market cap) with low liquidity and high volatility
- Historical performance shows high score-8 calls have underperformed (T+20 -26% on prior bullish report)
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3295757 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 13, 2026 7w ago | 8-K | $11.00 $12.00 | ▲ +9.09% | ▲ +10.84% | $12.44 (+13.09%) |
Aug 13, 2026 7w ago | Press Release | $11.00 $12.00 | ▲ +9.09% | ▲ +10.84% | $12.44 (+13.09%) |
Aug 6, 2026 8w ago | Press Release | $11.00 $11.23 | ▲ +2.09% | ▲ +1.49% | $12.44 (+13.09%) |
May 28, 2026 18w ago | Press Release | $12.20 $11.64 | ▼ −4.59% | ▼ −1.45% | $12.44 (+1.97%) |
May 20, 2026 19w ago | Press Release | $10.72 $12.14 | ▲ +13.25% | ▲ +12.51% | $12.44 (+16.04%) |
May 15, 2026 20w ago | 8-K | $10.72 $12.54 | ▲ +16.93% | ▲ +14.81% | $12.44 (+16.04%) |
May 15, 2026 20w ago | Press Release | $10.72 $12.54 | ▲ +16.93% | ▲ +14.81% | $12.44 (+16.04%) |
May 14, 2026 20w ago | Press Release | $10.51 $12.02 | ▲ +14.37% | ▲ +15.23% | $12.44 (+18.36%) |
May 12, 2026 20w ago | Press Release | $11.41 $12.19 | ▲ +6.84% | ▲ +8.56% | $12.44 (+9.03%) |
May 8, 2026 20w ago | Press Release | $10.95 $11.82 | ▲ +7.95% | ▲ +8.25% | $12.44 (+13.61%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access